Tara O’Meara is the Vice President of Clinical Development Operations at bluebird bio. Tara oversees a team responsible for the execution and analysis of bluebird bio’s lentiviral vector based gene therapy development programs. Currently bluebird bio has 4 active programs (Phase 1/2 through 3) using ex vivo gene therapy for: cerebral adrenoleukodystrophy, transfusion dependent thalassemia, sickle cell disease and multiple myeloma. bluebird bio’s objective is to develop and bring to market the most advanced products based on the transformative potential of gene therapy as a one-time treatment option for patients with severe genetic and rare diseases and cancer.
Prior to joining bluebird, Tara ran multiple clinical trials in 2 other rare diseases, LAL Deficiency (Synageva BioPharma) and Pompe disease (Genzyme Corporation). Tara served as the clinical project manager for the clinical trials that were used as the basis for the regulatory submissions that led to the approval of Myozyme™ (recombinant therapeutic protein for the treatment of Pompe disease) in the United States, Europe, and more than 40 additional countries worldwide. Tara has also been responsible for everything from small Phase II trials to very large, global Phase III trials in multiple therapeutic areas, including rare inherited diseases. Tara holds a BS in biology and a certificate in women’s studies from Tufts University. Tara also completed the Emerging Leaders Program at University Massachusetts, Boston in 2010.